Rubella Virus, Live Attenuated

CHEMBL6068355 Phase 4 Disetujui Vaccine component
Half-Life
—
Bioavailability
—
Protein Binding
—
Molecular Weight
— g/mol
LogP
—
Phase
4

Rubella virus live attenuated is a vaccine component containing the RA27/3 strain of attenuated rubella virus, used to prevent rubella (German measles) and congenital rubella syndrome. The live attenuated virus replicates minimally after injection, stimulating durable humoral immunity without causing significant disease. It is typically administered as part of the MMR (measles-mumps-rubella) combination vaccine.

Area Terapeutik

Pharmacokinetics (PK)

Pharmacodynamics (PD)

HBD / HBA

- / -

No targets recorded

Target interaction data is not yet available for this drug.

No interactions recorded

Drug interaction data is not yet available for this compound.

No side effects recorded

Side effect data is not yet available for this drug.

Pertanyaan yang Sering Diajukan

Rubella virus live attenuated is a vaccine component containing the RA27/3 strain of attenuated rubella virus, used to prevent rubella (German measles) and congenital rubella syndrome. The live attenuated virus replicates minimally after injection, stimulating durable humoral immunity without causing significant disease. It is typically administered as part of the MMR (measles-mumps-rubella) combination vaccine.

Yes, Rubella Virus, Live Attenuated is an approved drug. It has reached clinical phase 4. It is classified as a Vaccine component.

References & Data Sources

  • ChEMBL — European Bioinformatics Institute (EBI). CHEMBL6068355. Open-access bioactivity database.

Data aggregated from publicly available pharmacological databases. Last updated 2026-02-27.

Penyangkalan Medis

This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.

Data sources: ChEMBL, PubChem, DailyMed.